Exploring the therapeutic potential of cinnamoyl derivatives in attenuating inflammation in lipopolysaccharide-induced Caco-2 cells.
Marcella RealeErica CostantiniLisa AielliAnnalisa Di RienzoGiuseppe Di BiaseAntonio Di StefanoIvana CacciatorePublished in: Future medicinal chemistry (2024)
Aim: In gastrointestinal (GI) diseases, lipopolysaccharide (LPS) exacerbates gut-barrier dysfunction and inflammation. Cinnamoyl derivatives show potential in mitigating LPS-induced inflammation. Materials & methods: We assessed intestinal epithelial barrier function using Trans -epithelial electrical resistance values and measured inflammatory mediators through real-time PCR and ELISA in Caco-2 cells. Results: LPS treatment increased IL-6, IL-1β, TNF-α, PGE2 and TRL4 expression in Caco-2 cells. Pre-treatment with DM1 (1 or 10 μM) effectively countered LPS-induced TLR4 overexpression and reduced IL-6, IL-1β, TNF-α and PGE2 levels. Conclusion: DM1 holds promise in regulating inflammation and maintaining intestinal integrity by suppressing TLR4 and inflammatory mediators in Caco-2 cells. These findings suggest a potential therapeutic avenue for GI diseases.
Keyphrases
- inflammatory response
- lps induced
- induced apoptosis
- oxidative stress
- lipopolysaccharide induced
- cell cycle arrest
- toll like receptor
- rheumatoid arthritis
- signaling pathway
- cell proliferation
- poor prognosis
- risk assessment
- machine learning
- skeletal muscle
- climate change
- real time pcr
- weight loss
- anti inflammatory
- transcription factor
- insulin resistance
- smoking cessation
- nuclear factor
- human health